We are developing next-generation stool DNA diagnostics, which leverage the power of our proprietary and patented technologies. Our goal?
To prevent colon cancer through early detection.
Why is it important to detect colon cancer early?
Colon cancer is the 2nd leading cancer killer in the US (around 50,000 deaths per year in the US). Thankfully, it is curable if found early. For example, if the earliest form of cancer–called pre-cancerous polyps, or pre-cancer for short–is detected, then the survival rate is almost 100%. Once found, we can remove pre-cancer to stop it from developing into more serious, later-stage cancer, potentially saving millions of lives.
What options are there for colon cancer screening?
The American Cancer Society recommends colon cancer screening starting at age 45. Both colonoscopies and stool DNA tests are viable options. Often colonoscopies are seen as the gold standard because they have high cancer detection rates. However, colonoscopies are not convenient because they require taking purgatives and then fasting before an invasive procedure involving sedatives.
For many Americans, stool DNA tests are quickly becoming a better option because they are much more convenient than colonoscopies and also have excellent cancer detection rates. There is no invasive procedure and no preparation required for patients to perform a stool DNA test.
How does GLC aim to revolutionize colon cancer screening in the US?
One downside to stool DNA tests is their low pre-cancer detection rate. This has prevented stool DNA tests from reaching mass adoption by both patients and physicians.
Utilizing next-generation patented technology, GLC has developed a stool DNA test with aims to detect the majority of pre-cancer, detecting precancer at a rate of 82%.